Mereo and Oncologie announced a global license agreement for the development of a drug for patients with pretreated ovarian cancer.
Mereo BioPharma Group (NASDAQ:MREO) and Oncologie announced a global license agreement for the development and commercialization of navicixizumab, an antibody currently being studied in patients with advanced, pretreated ovarian cancer.
As quoted in the press release:
Navicixizumab previously completed a Phase 1a monotherapy study in patients with various types of refractory solid tumors and is one of two product candidates Mereo acquired through its 2019 merger with OncoMed Pharmaceuticals, Inc. In October 2019, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation to navicixizumab and has agreed in principle on the design of a study that could potentially support accelerated approval for navicixizumab in a heavily pretreated, platinum-resistant ovarian cancer patient population.